Largest health center in Italy uses SOPHiA DDM™ Platform on Microsoft Azure to expand data-driven medicine capabilities while ensuring accuracy and security
BOSTON and ROLLE, Switzerland, November 28, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage of the SOPHiA DDM™ Platform to support research on homologous recombination repair (HRR) biomarkers that indicate treatment options for ovarian, prostate, breast and pancreatic cancers.
Città della Salute e della Scienza di Torino is part of one of the largest university hospitals and health systems in Europe. As such, the institution cares for thousands of people each year and is responsible for the efficient, accurate and secure analysis of a vast amount of genomic data.
“The ability to partner with a technology provider that can help efficiently decipher the expansive amount of data from raw next generation sequencing (NGS) data – and guarantee security of such data – is of paramount importance to our institution,” said Dr. Barbara Pasini, Head of the Medical Genetics Unit, Città della Salute e della Scienza di Torino. “The SOPHiA DDM™ Platform, which leverages the cloud infrastructure of Microsoft Azure, answers our needs by providing the secure analysis of all data coupled with simplified insights.”
NGS is helping to revolutionize the research of several cancers and rare diseases, yet it yields extremely large and complex datasets for analysis. The Microsoft Azure-powered SOPHiA DDM™Platform uses artificial intelligence and machine learning with patented technologies to streamline the analysis of raw NGS data and generate biologically actionable insights, which can speed the research process and ultimately lead to better health outcomes.
SOPHiA GENETICS has worked with Microsoft to further the democratization of data-driven medicine. Using the secure, cloud-based infrastructure of Microsoft Azure, SOPHiA GENETICS offers a solution via the SOPHiA DDM™ Platform that helps break the data silos and facilitate data-sharing and research advancements.
“The SOPHiA DDM™ Platform has helped us to optimize our research in specific cancer types, such as the recently added analysis on ovarian and prostate tumors, that may contain somatic BRCA1 and BRCA2 gene variants. The platform has enabled our researchers analyzing tumor samples to more quickly come to data-driven conclusions and move towards the practice of precision medicine,” said Dr. Francia di Celle and Dr. Bonello, of the Molecular Pathology Laboratory, Città della Salute e della Scienza di Torino.
“The partnership between SOPHiA GENETICS and Microsoft provides clients such as Città della Salute e della Scienza di Torino with convenience and flexibility to implement the technology solutions necessary to suit their needs, while ensuring peace of mind that their data is secure,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “We are excited to be expanding our work with organizations that recognize the innovative power of precision medicine and the elevated standard of care it can provide to patients.”
“Together we’re not only enhancing operational efficiency but also unveiling unprecedented potential within medical and genomic data landscapes by leveraging Azure for data ingestion and data management in the SOPHiA DDM™ Platform. This new era of cooperation allows healthcare providers to bolster their capabilities in managing multimodal data, which paves the way for deriving profound insights conducive to enhanced patient care,” said Elena Bonfiglioli, General Manager, WW Healthcare, Global Pharma and Life Sciences, Microsoft. “Microsoft is pleased to continue supporting SOPHiA GENETICS’ mission to democratize data-driven medicine by providing secure and scalable cloud infrastructure.”
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn,Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native software company in the healthcare space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA DDM™ miniHRS Solution is available as a CE-IVD product for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
